Atlas Trials

Study of Tixagevimab/Cilgavimab and Regdanvimab Efficacy for Treatment of COVID-19

Clinical trial NCT05982704 · UNKNOWN

Trial details

NCT number
NCT05982704
Sponsor
City Clinical Hospital No.52 of Moscow Healthcare Department
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Coronavirus Infections
Start date
2022-08-18
Primary completion
2022-09-19
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.